Tech Company Financing Transactions

Calistoga Pharmaceuticals Funding Round

Calistoga Pharmaceuticals, based in Seattle, raised $40 million from Alta Partners, Amgen Ventures and Frazier Healthcare Partners.

Transaction Overview

Announced On
6/30/2010
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Proceeds Purpose
The funds will be used to advance Calistoga Pharmaceuticals' drug development pipeline of isoform-selective PI3K inhibitors. CAL-101, an oral, delta selective PI3K inhibitor, is currently being evaluated as a single agent in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) and in combination with rituximab or bendamustine in patients with relapsed or refractory iNHL or CLL.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2101 - 4th Ave. 1960
Seattle, WA 98121
USA
Email Address
Overview
Calistoga Pharmaceuticals, is developing a drug candidate acquired from Icos that has potential to treat various forms of cancer.
Profile
Calistoga Pharmaceuticals LinkedIn Company Profile
Social Media
Calistoga Pharmaceuticals Company Twitter Account
Company News
Calistoga Pharmaceuticals News
Facebook
Calistoga Pharmaceuticals on Facebook
YouTube
Calistoga Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Carol Gallagher
  Carol Gallagher LinkedIn Profile  Carol Gallagher Twitter Account  Carol Gallagher News  Carol Gallagher on Facebook
Chief Financial Officer
Andrew Guggenhime
  Andrew Guggenhime LinkedIn Profile  Andrew Guggenhime Twitter Account  Andrew Guggenhime News  Andrew Guggenhime on Facebook
Chief Medical Officer
Albert Yu
  Albert Yu LinkedIn Profile  Albert Yu Twitter Account  Albert Yu News  Albert Yu on Facebook
VP - R & D
Langdon Miller
  Langdon Miller LinkedIn Profile  Langdon Miller Twitter Account  Langdon Miller News  Langdon Miller on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/30/2010: EpiEP venture capital transaction
Next: 6/30/2010: Arcxis Biotechnologies venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary